Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-06-22FDA Approved: ERLOTINIB — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original application for a generic erlotinib product. Erlotinib is used to treat certain cancers…
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer [Phase 2]
Phase 2 trial update of crizotinib in ROS1-translocated lung cancer (EU CROSS) completed.
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer [Phase 3]
Phase III study evaluating almonertinib after chemoradiation in patients with stage III unresectable non-small cell lung cancer is currently…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer [Phase 3]
Phase 3 trial update on neoadjuvant or adjuvant chemotherapy in operable non-small-cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2022-06-10Clinical Trial Update: A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial update for Envafolimab in stage III non-small cell lung cancer is reported as ongoing with unknown status.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel [Phase 2]
Phase II trial updates sequential consolidation with pembrolizumab followed by nab-paclitaxel in non-small cell lung cancer; study completed…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) [Phase 3]
A Phase 3 trial evaluating pembrolizumab with or without lenvatinib in PD-L1–positive treatment-naïve non-small cell lung cancer has complet…
-
CLINICAL_TRIALS trial_result · 2022-05-27Clinical Trial Update: Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC [Phase 2]
Phase 2 trial update for tislelizumab plus bevacizumab and paclitaxel (pc) in untreated EGFR-mutant and high PD-L1 non-squamous non-small ce…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy [Phase 2]
Phase 2 clinical trial evaluating platinum-based chemotherapy plus ramucirumab in advanced non-small cell lung cancer patients who progresse…
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Zydus Lifesciences Limited)
The FDA approved a generic pemetrexed disodium product (PEMETREXED DISODIUM) from Zydus Lifesciences Limited.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED DISODIUM — Original Application (Dr. Reddys Laboratories Inc)
FDA approval of a generic pemetrexed disodium product (ANDA) submitted by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s original application for a generic pemetrexed product.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' original application for pemetrexed disodium, a generic version of pemetrexed for cancer indications.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' original application for a generic pemetrexed disodium product. This makes a pemetrexed disodium ge…
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (BluePoint Laboratories)
FDA approved a generic pemetrexed disodium product (PEMETREXED) from BluePoint Laboratories under an original ANDA.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Sagent Pharmaceuticals)
FDA approves an original generic application for pemetrexed disodium (Pemetrexed) by Sagent Pharmaceuticals. Pemetrexed is used in the treat…
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (BluePoint Laboratories)
FDA approved the original application for a generic version of pemetrexed disodium (PEMETREXED) from BluePoint Laboratories.
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Waverley Pharma Inc)
FDA approved the original application for pemetrexed disodium (generic PEMETREXED) from Waverley Pharma Inc. This approval covers the drug's…
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' Original Application for a generic pemetrexed product (PEMETREXED), authorizing its manufacture and sal…
-
FDA approval · 2022-05-25FDA Approved: PEMETREXED — Original Application (Fresenius Kabi USA, LLC)
FDA approves Fresenius Kabi USA, LLC's original ANDA for pemetrexed disodium (generic pemetrexed), allowing marketing of a generic pemetrexe…
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) [Phase 3]
This document provides an update on the NEPTUNE Phase 3 trial comparing durvalumab with tremelimumab versus standard-of-care as first-line t…
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer [Phase 4]
A Phase 4 clinical trial evaluating penpulimab combined with anlotinib as neoadjuvant therapy for resectable non-small cell lung cancer is o…
-
CLINICAL_TRIALS trial_result · 2022-05-24Clinical Trial Update: SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors [Phase 2]
Phase 2 clinical trial update evaluating SBRT for oligoprogressive non-small cell lung cancer after first-line immune checkpoint inhibitors.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) [Phase 2]
Phase 2 clinical trial evaluating salvage surgery after downstaging of advanced non-small cell lung cancer by targeted therapy.
-
CLINICAL_TRIALS trial_result · 2022-05-19Clinical Trial Update: A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive [Phase 2]
Phase IIb trial update for BPI-7711 capsules in non-small cell lung cancer patients with T790M mutation (Phase 2, completed).